Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402)
Introduction
The prognosis of hepatocellular carcinoma (HCC) is poor because curative therapies are dedicated to a small proportion of patients with early stage of the disease.1 At intermediate or advanced stages there is no standard treatment.1, 2 Transarterial Lipiodol Chemoembolisation (TACE) is a controversial intervention with still uncertain efficacy,3, 4, 5, 6, 7, 8, 9 even if the two most recent randomised controlled clinical trials (RCT) identified overall survival (OS) benefit.8, 9 Two meta-analyses 10, 11 showed that chemoembolisation significantly improved OS although a third meta-analysis12 failed to demonstrate a significant advantage. The efficacy of antiestrogen therapy in advanced HCC is also controversial. In the early 1990s, a positive effect was attributed to tamoxifen.13, 14 However, the recent meta-analyses of Llovet and colleagues11 and Nowak and colleagues15 and a large RCT,16 concluded that tamoxifen therapy did not provide any significant survival benefit.
Thus, we conducted a French multicentre randomised controlled phase III trial to compare the effect of the TACE-tamoxifen with tamoxifen alone on OS and quality of life (QoL) in patients with unresectable HCC.
Section snippets
Selection of patients
Inclusion criteria were patients with liver cirrhosis (diagnosis of cirrhosis was obtained by histopathology, clinical presentation or laboratory findings) and unresectable HCC based on biopsy, or persistently elevated serum α-fetoprotein (AFP) levels (>500 ng/mL) with one typical imaging finding (ultrasonography, CT scan or magnetic resonance imaging). These criteria were near from the Barcelona criteria.1 A signed informed consent was required.
Exclusion criteria were age older than 75 years,
Results
From May 1995 to June 2002, 138 patients in 15 French centres were randomly assigned to the TACE group (70 patients) or the Tamoxifen group (68 patients). Eligible patients were 62 in the TACE group and 61 in the Tamoxifen group (Fig. 1). The two groups were well balanced with respect to demographic, clinical or biological characteristics (Table 1). The majority of patients (76%) had alcoholic cirrhosis with well-compensated liver function (Child-Pugh class A: 70%) and Okuda stage I (71%) with
Intent-to-treat analyses
By 1 August 2004, 58 and 56 had, respectively, died in the TACE and the Tamoxifen groups. The median follow-up was 12.4 months in the TACE group and 11.0 months in the Tamoxifen group. OS (Fig. 2) did not differ according to treatment arm (P = .68, log-rank test). At 1 and 2 years, the survival rates were 51% (95% CI, 38–63%), and 25% (15–37%) in the TACE group and 46% (33–58%) and 22% (12–33%) in the Tamoxifen group (P = .68). The median OS was 13.8 months (95% CI, 7.6–16.8) in the TACE group and
Discussion
This study suggests that TACE improves neither survival nor QoL in patients with well-preserved liver function and Okuda stages I and II.
Our results were not in agreement with the two most recent RCT8, 9 and two meta-analysis.10, 11 However, they are consistent with two French trials.5, 7 The French studies were characterised by a large number of patients with alcohol-induced cirrhosis, whereas the Hong Kong and Barcelona trials included patients with hepatitis B or C virus-induced cirrhosis (
Conflict of interest statement
None declared.
Acknowledgements
We thank the following physicians for their participation to this study: S. Agostini (Marseille), F. Audemar (Strasbourg), G. Bommelaer (Clermont-Ferrand), C. Bonny (Clermont-Ferrand), F. Boudghene (Paris), B. Bour (Le Mans), J.P. Cercueil (Dijon), W. Chbeir (Le Mans), S. Dohin (Le Mans), G. Debillon (Orléans), B. Gollentz (Belfort), M. Grand (Reims), M. Guillot (Bourgoin-Jallieu), P. Hillon (Dijon), J.L. Jouve (Dijon), D. Krause (Dijon), J.L. Legoux (Orléans), C. Legrand (Nantes), G. Lepeu
References (48)
- et al.
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona – 2000 EASL conference
J Hepatol
(2001) - et al.
Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma – a randomized controlled trial
Gastroenterology
(1988) - et al.
A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma
J Hepatol
(1990) - et al.
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial
J Hepatol
(1998) - et al.
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
Hepatology
(2002) - et al.
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
Lancet
(2002) - et al.
Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival
Hepatology
(2003) - et al.
Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma
J Hepatol
(1994) - et al.
J Chron Dis
(1981) - et al.
Clinical Significance Consensus Meeting Group Assessing the clinical significance of single items relative to summated scores
Mayo Clin Proc
(2002)